Study design
Hashimoto’s thyroiditis, abnormal liver function, liver disease, disturbance of blood coagulation, substance abuse
ACUTE INFECTION, MYOCARDIAL INFARCTION, DISEASE, LIVER DISEASE, LYMPH NODE METASTASIS, PAPILLARY THYROID CARCINOMA
This was a multicenter, randomized, blank-controlled study (ChiCTR2300068502 Based on the different resection ranges of the primary lesions, the clinical trials were divided into two subgroups: unilateral lobectomy and total thyroidectomy.Patients satisfying the following criteria were recruited in the unilateral lobectomy group: (1) preoperative and intraoperative diagnosis of untreated, unilateral, and single-focal papillary thyroid carcinoma; (2) no cervical lymph node metastasis on imaging examination, and no indication of lateral neck lymph node dissection; (3) unilateral lobectomy plus isthmectomy with ipsilateral central lymph node dissection; (4) age 18–70 years; (5) results of preoperative laboratory blood test–neutrophils (ANC) ≥1.5×10Patients who met the following criteria were recruited into the total thyroidectomy group: (1) preoperatively and intraoperatively diagnosed with untreated, unilateral, and single-focal papillary thyroid carcinoma; (2) no enlarged lymph nodes on physical examination; and lateral cervical lymph node metastasis on imaging examination; (3) total/near total thyroidectomy, ipsilateral central and lateral lymph node dissection; (4) age 18–70 years; (5) preoperative laboratory blood test results (ANC≥1.5×10Patients were excluded if they met one or more of the following criteria: (1) concomitant Hashimoto’s thyroiditis; (2) active stage of liver disease or abnormal liver function, with ALT, AST, and TBIL≥2 times the ULN; (3) renal function impairment, Cr≥2 times the ULN or BUN≥2 times the ULN; (4) a history of alcohol, drug, or substance abuse and disturbance of blood coagulation; and (5) a history of serious uncontrolled medical disease, recent myocardial infarction, or acute infection.